Background-The ventricular arrhythmia torsade de pointes (TdP) occurs after QT interval prolongation and is associated with sudden cardiac death. The afterdepolarizations that initiate TdP are facilitated by protein kinase A and the multifunctional Ca 2ϩ /calmodulin-dependent protein kinase II (CaM kinase). Methods and Results-In this study, we evaluated the feasibility of suppression of TdP through systemic therapy with kinase inhibitory agents in an established animal model. Under control conditions, TdP was inducible in 6 of 8 rabbits.
D
rugs that prolong action potential (AP) repolarization can be antiarrhythmic through the lengthening of tissue refractoriness or the elimination of an excitable gap, thereby extinguishing reentry. 1 AP prolongation also has proarrhythmic consequences by causing afterdepolarizations that trigger torsade de pointes (TdP) and that are associated with sudden death. An agent that could preserve the beneficial effects of AP prolongation without inducing afterdepolarizations and TdP thus is an important goal for antiarrhythmic drug development. Protein kinase A (PKA), Ca 2ϩ /calmodulindependent protein kinase II (CaM kinase), and increased intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) have been implicated as causes of afterdepolarizations in isolated cardiac myocytes [2] [3] [4] [5] [6] and isolated Langendorff-perfused heart models. 7 PKA and CaM kinase both likely enhance the probability of afterdepolarizations by increasing [Ca 2ϩ ] i , and the systemic administration of the sarcoplasmic reticulum (SR) Ca 2ϩ uptake and release antagonists flunarizine 8 and ryanodine 8, 9 prevents TdP. PKA and CaM kinase both act at L-type Ca 2ϩ channels 10, 11 and SR Ca 2ϩ stores [12] [13] [14] to increase [Ca 2ϩ ] i . Afterdepolarizations are oscillations in cell membrane potential 15, 16 that are often associated with increased SR Ca 2ϩ release and are suppressed by CaM kinase inhibition in isolated Langendorff-perfused hearts 7 and cardiac myocytes. 3 Recently, AP prolongation in response to the class III antiarrhythmic drug clofilium was shown to increase CaM kinase activity 7 when afterdepolarizations were induced. The application of a CaM kinase inhibitor prevented the increase in CaM kinase activity without shortening AP duration. 7 Afterdepolarizations are also associated with conditions favoring increased PKA activity, 4 -6 and ␤-adrenergic receptor antagonists likely exert an antiarrhythmic action in long QT-related arrhythmias by decreasing PKA activity. Because of the known link among PKA, CaM kinase, and triggered arrhythmias, it is likely that inhibition of these kinases may prevent TdP. However, even the acute hemodynamic feasibility of the treatment of arrhythmias with systemically administered kinase inhibitory agents is unknown.
An ideal therapeutic kinase inhibitory agent would be systemically bioavailable, cell membrane permeant, highly specific, and potent and would not be associated with side effects. At the present, no such inhibitors are thought to exist.
is a water-soluble, cell membrane-permeant competitive antagonist of calmodulin. 17 17 In this study, the effects of these 2 kinase inhibitors, administered systemically, were tested in an established animal model of TdP.
Methods

Rabbit Arrhythmia Model
The in vivo rabbit model of TdP was implemented as described by Carlsson et al 21 with minor modifications. In brief, male New Zealand rabbits (weight 2.5 to 3.0 kg) were initially anesthetized with 35 mg/kg ketamine IM and 5 mg/kg xylazine IM. Supplemental xylazine (1 mg/kg IM) and ketamine (15 mg/kg IM) were administered 15 minutes after the initial doses to maintain adequate anesthesia (loss of withdrawal reflex) throughout the experiment. Rabbits were mechanically ventilated with room air (Harvard Rodent Ventilator), and the adjustment of respiratory parameters was guided by arterial blood gases (PO 2 84 to 101 mm Hg, PCO 2 33Ϯ0.6 mm Hg, pH 7.44Ϯ0.03). Arterial blood pressure was continuously monitored with a femoral artery cannula. A minimum 10-minute stabilization period was used before any further intervention. Methoxamine (70 nmol ⅐ kg Ϫ1 ⅐ min Ϫ1 IV) was then infused for 10 minutes before starting clofilium (100 nmol ⅐ kg Ϫ1 ⅐ min Ϫ1 IV), after which both agents were continued simultaneously for 30 minutes or until TdP induction. Animals were euthanized with 50 mg/kg pentobarbital IV after the study. All procedures performed in the present study were approved by the Vanderbilt University Animal Care Committee.
Systemic Application of Kinase Inhibitors
Control animals were infused with 5% dextrose solution (20 mL total IV) at the same time as methoxamine infusion. The experimental group animals were infused with 5% dextrose solution (20 mL total IV) containing the indicated concentration of W-7 or H-8 (both from BIOMOL Research Laboratories) during methoxamine infusion. A separate group of 4 rabbits were pretreated with 50 mol/kg W-7 and observed for 25 minutes without TdP after the methoxamine and clofilium infusion, as described. Then, 1 mL of the vehicle for the L-type Ca 2ϩ channel agonist BAY K 8644 was administered, which did not elicit TdP or any hemodynamic changes. BAY K 8644 (300 nmol/kg IV bolus in 1 mL polyethylene glycol/ethanol/saline [5:5:90 vol/vol]; BIOMOL Research Laboratories) was then administered over 30 seconds, and the animal was observed for 5 minutes.
ECG Recording
Standard surface ECG limb leads (I, II, III, aVF, aVL, and aVR) and a midchest lead positioned at the sternal notch (V) were continuously monitored and recorded at a paper speed of 100 mm/s (Electronics for Medicine, Honeywell Inc). ECG intervals were analyzed with a digitizing tablet (Summagraphics Corp) interfaced to a microcomputer. A 2-channel ECG was continuously recorded on audiotape and analyzed with the use of an ambulatory ECG monitoring system (Rozinn Electronics Inc).
TdP
TdP was defined as Ն6 consecutive beats of polymorphic ventricular tachycardia.
ECG Interval Measurements
ECG intervals were measured as the average from 3 consecutive beats with a single lead providing the clearest end of the QT interval (usually lead II or III).
QT Interval
QT interval measurements were recorded from the onset of the QRS complex to the return of the T wave to the isoelectric line ( Figure 1 ). When present at Ͼ25% of the amplitude of the T wave, the U wave was included in the QT duration measurement. 22 
Corrected QT Interval
The QT interval was corrected (QT c ) according to the method of Carlsson et al 23 for rabbits with the formula QT c ϭ QTϪ0.175(RRϪ300).
RR Interval
The RR interval was measured from the onset of consecutive QRS complexes.
Chemicals
All chemicals were obtained from Sigma Chemical Co, unless otherwise noted, and solutions were prepared fresh daily from concentrated stock solutions. 
Statistical Analysis
MeanϮSD values was calculated for continuous variables, and absolute and relative frequencies were measured for discrete variables. Continuous variables were compared between groups with the use of Student's t test or 1-way ANOVA as appropriate, and categorical variables were compared with the use of Fisher's exact test. Values of PՅ0.05 were considered statistically significant.
Results
Induction of TdP
After treatment with methoxamine and clofilium, a consistent sequential pattern of bradycardia, QT interval prolongation, and isolated premature ventricular contractions (PVCs) leading to long-short coupling intervals preceded TdP initiation ( Figure 1A) . The time to the first PVC was significantly increased in W-7-treated animals (19.0Ϯ8.0 minutes) compared with control (7.7Ϯ5.9 minutes, PϽ0.01) or H-8 -treated (5.7Ϯ4.4 minutes, PϽ0.001) animals. TdP was induced in 6 of 8 rabbits under control conditions (Figure 2 ).
Prevention of TdP by W-7 and H-8
Both W-7 and H-8 prevented TdP inducibility in a dosedependent manner (Figure 2) , consistent with the reported roles of CaM kinase and PKA in the facilitation of afterdepolarizations. TdP suppression was significant at 50 mol/kg for W-7 and at 10 mol/kg for H-8. TdP induction in W-7-pretreated animals tended to occur later after the infusion of methoxamine and clofilium than in controls. TdP was induced with the L-type Ca 2ϩ current agonist BAY K 8644 after W-7 (50 mol/kg) pretreatment (nϭ4), suggesting that these animals remained capable of developing TdP by a calmodulin-and CaM kinaseindependent pathway (Figure 3 ).
QT Interval Not Affected by W-7
QT interval prolongation favors induction of TdP, so suppression of TdP by kinase inhibitory agents could simply reflect QT interval shortening. 24 Marked QT and QT c interval prolongation occurred after treatment with methoxamine and clofilium, and this prolongation was not affected by pretreatment with W-7 ( Figures 1B and 4) . Treatment with H-8 (10 mol/kg) resulted in significant QT and QT c interval shortening (Figure 4) . Thus, suppression of TdP by W-7, but not by H-8, was independent of QT interval prolongation.
Prevention of TdP by W-7 Not Due to Increase in Heart Rate
Because inducibility of TdP is known to be favored at low heart rates, 25 one possible mechanism for TdP suppression could be an increase in heart rate. The heart rate slowed during the course of methoxamine and clofilium infusion but was not significantly different from control rates in W-7 (50 mol/kg)-treated animals ( Figure 5) . In contrast, H-8 (10 mol/kg) increased heart rate at all time points ( Figure 5 ). The suppression of TdP by W-7, but not by H-8, was independent of an effect on heart rate.
Kinase Antagonist Therapy Was Acutely Hemodynamically Tolerated
The infusion of W-7 or H-8 at levels adequate to suppress TdP was not associated with a decrease in systolic ( Figure  6A ) or diastolic ( Figure 6B ) blood pressure. On the contrary, W-7-treated animals had a tendency to increase both systolic and diastolic blood pressure. Thus, the systemic administration of these kinase inhibitory agents was acutely hemodynamically tolerated in this animal model.
Discussion
Serine/Threonine Kinases in Cardiovascular System
Because serine/threonine kinases are ubiquitous and regulate a diverse array of target proteins in the cardiovascular system, the consequences of the use of systemic kinase inhibitory agents are unknown. In the cardiovascular system, PKA and PKC are both known to affect heart rate, 26, 27 and PKA, 28, 29 PKC, 30 -33 protein kinase G, 28, 34 and CaM kinase 10, 13, 14, [35] [36] [37] all participate in the regulation of smooth and cardiac muscle [Ca 2ϩ ] i . Thus, the acute hemodynamic response to the systemic application of these inhibitory agents could be an important limitation in the development of novel approaches to antiarrhythmic therapy with the use of serine/threonine kinase inhibitory agents. On the other hand, the inhibition of the cardiac cell membrane ionic currents and exchangers responsible for afterdepolarizations may be accomplished with sufficiently low concentrations of kinase inhibitory agents to avoid systemic toxicities. New approaches to drug development through the use of combinatorial chemistry may lead to agents with increased potency and specificity compared with currently available agents. 38 
Role of Serine/Threonine Kinases in Arrhythmias
Both PKA and CaM kinase are thought to have proarrhythmic actions due to enhancement of L-type Ca 2ϩ current. 3-5,10 PKA has long been an "indirect" antiarrhythmic drug target because clinically available ␤-adrenergic receptor antagonists prevent ␤-agonist mediated increases in PKA activity. These agents have been shown to reduce sudden cardiac death 39 and are used in patients with long QT syndromes. 25 In contrast to PKA, CaM kinase activity is generally not attributable to the activation of a single receptor type but rather increases in response to elevated [Ca 2ϩ ] i . 40 CaM kinase activity increases during AP prolongation and afterdepolarizations, and CaM kinase inhibition prevents afterdepolarizations without shortening AP duration in isolated hearts. 7 Although cell membrane permeant kinase inhibitors have long been available as pharmacological and research tools, 17 the ubiquitous nature of these kinases has perhaps been viewed as a potential obstacle to systemic kinase inhibition for therapy of cardiac arrhythmias. The findings presented here suggest that at least for acute administration, 2 such agents are hemodynamically tolerated at concentrations effective for the suppression of arrhythmias.
Kinase Inhibitory Agents
Although a role of CaM kinase in the facilitation of afterdepolarizations in isolated cells has been inferred with the use of highly specific inhibitory peptides, 2,3 no cell membranepermeable agents with similar specificity adequate for systemic administration presently exist. Both W-7 and H-8 can act at many different cellular targets by virtue of their broad kinase inhibitory actions and because these agents may directly inhibit nonenzyme proteins such as ion channels. 7, 10, 41 The finding that systemic blood pressure increased after W-7 administration indicates that L-type Ca 2ϩ current inhibition was not a predominant action at the concentration used to suppress TdP. Thus, a limitation of this study is that the suppression of TdP cannot be definitively ascribed to CaM kinase or PKA inhibition. However, the finding that TdP suppression did occur as predicted in previous cellular and in vitro studies without untoward hemodynamic consequences is an important step for the demonstration of the feasibility of this novel approach to antiarrhythmic therapy.
Prevention of TdP In Vivo
The suppression of TdP by both W-7 and H-8 occurred in a dose-dependent manner. H-8 did not suppress TdP at concentrations predicted to be selective for PKA inhibition, although the effective intracellular concentration is unknown. At higher concentrations, compatible with PKA and PKC inhibition, H-8 was effective in the suppression of TdP. W-7 at concentrations predicted to inhibit calmodulin-dependent processes, including those mediated by CaM kinase, was also effective in the suppression of TdP. The findings that PVC onset was delayed by W-7 suggests that CaM kinase inhibition reduced the probability of a triggering event (ie, an afterdepolarization). Our findings do not provide information regarding possible affects of kinase inhibitors on the substrate for arrhythmia maintenance (eg, dispersion of repolarization). It will be important to better define the mechanisms of action of kinase inhibitory agents in TdP prevention in future studies through the measurement of afterdepolarizations and QT interval dispersion. Although the rabbit TdP model of the present study is highly reproducible and widely used, studies in other models, and ultimately in humans, will be required to determine the potential clinical use of kinase inhibition as a therapy for arrhythmias.
Proarrhythmia and QT Interval Prolongation
The inhibition of TdP by W-7 was different from that seen after treatment with H-8. The most striking difference was that W-7 did not result in a decrease in QT interval, whereas H-8 treatment significantly shortened the QT interval. QT interval shortening suggests that effects other than kinase inhibition may be important for TdP suppression with H-8. Alternately, inhibition of PKA (and perhaps other kinases) with H-8 shortens the QT interval. The suppression of TdP without shortening of the QT interval suggests that CaM kinase inhibitory agents may allow separation of the beneficial actions of QT prolongation (ie, increased inotropy and the class III antiarrhythmic effect) from the proarrhythmic actions (ie, afterdepolarizations and TdP). Although other mechanisms might be operative, the data presented here raise the strong possibility that direct targeting of intracellular kinases is feasible and produces important antiarrhythmic actions.
